Acromegaly
Welcome,         Profile    Billing    Logout  
 24 Companies   9 Products   9 Products   6 Mechanisms of Action   50 Trials   3648 News 


«12...4243444546474849505152...5960»
  • ||||||||||  Somavert (pegvisomant) / Pfizer, NN1213 / Novo Nordisk
    Enrollment closed:  I-Con Study: Strict IGF-1 Control in Acromegaly (clinicaltrials.gov) -  Apr 2, 2020   
    P3,  N=35, Active, not recruiting, 
    No complications related to young age appeared. Recruiting --> Active, not recruiting
  • ||||||||||  Evaluation of Arterial Stiffness in Acromegaly Patients (ENDOExpo) -  Apr 1, 2020 - Abstract #ENDO2020ENDO_4241;    
    Acromegaly is associated with increased morbidity and mortality primarily attributed to cardiovascular problems. We thought that it may be a guiding method in disease management since it can be an early marker of cardiovascular risk.Keywords: acromegaly, pulse wave velocity, aortic augmentation index
  • ||||||||||  Prognostic Factors and Mortality According to the Structural and Functional Classification of Acromegaly (ENDOExpo, Booth 225) -  Apr 1, 2020 - Abstract #ENDO2020ENDO_4233;    
    Independent parameters related with disease activity were acromegaly types 2 and 3 (OR=2.7; IC95% 1.9-6.7, p=0.005), and radiotherapy (OR=0.36, 0.18-0.70, p=0.003). Conclusions : Type 3 acromegaly patients showed higher frequency of comorbidities, disease activity, and risk of mortality, adjusted for treatment, than type 2 and type 1 patients.
  • ||||||||||  Octreosphere (octreotide extended release) / Xbrane, Sandostatin LAR Depot (octreotide acetate) / Novartis, adecatumumab (MT201) / Amgen
    Extended Release Octreotide Pharmacokinetics in Healthy Subjects After Subcutaneous Injection of MTD201 (ENDOExpo) -  Apr 1, 2020 - Abstract #ENDO2020ENDO_4099;    
    Reduced plasma IGF-1 concentrations were maintained throughout the study period. Unlike marketed octreotide depot products, MTD201 can be simply and rapidly reconstituted in WFI to give a stable suspension injectable via 21G needle in a 1.5mL volume.
  • ||||||||||  A Mysterious Multiple Endocrine Neoplasia (MEN) Like Syndrome (ENDOExpo) -  Apr 1, 2020 - Abstract #ENDO2020ENDO_3850;    
    The biochemical phenotype of pheochromocytoma (elevated metanephrines) is consistent with cluster 2 tumors of kinase signaling pathway as seen in tumors of MEN syndrome and neurofibromatosis. We hope to gain more insight via whole exome sequencing to evaluate for potential novel gene mutation(s).
  • ||||||||||  Novel Genetic Variant of Carney Complex With Acromegaly (ENDOExpo) -  Apr 1, 2020 - Abstract #ENDO2020ENDO_3760;    
    The diagnosis has many deleterious consequences if not treated early. Additionally, this case represents a novel pathologic variant of PRKAR1A that has not previously been identified in Carney complex.
  • ||||||||||  Review, Journal:  Pituitary Tumors in Pregnancy. (Pubmed Central) -  Mar 29, 2020   
    Diagnosing and managing pituitary tumors during pregnancy involve many challenges, including the effect of hormone excess or deficiency on pregnancy outcome, changes in the pituitary or pituitary-related hormones, changes in tumor size, and the impact of various treatments of pituitary tumors on maternal and fetal outcomes. This article discusses the diagnosis and treatment of patients with prolactinomas, acromegaly, Cushing disease, and other pituitary tumors during pregnancy.
  • ||||||||||  Clinical, Journal:  Markers of Metabolic Syndrome in Patients with Pituitary Adenoma: A Case Series of 303 Patients. (Pubmed Central) -  Mar 29, 2020   
    In patients developing pituitary failure after treatment, age, waist circumference, plasma glucose, low-density lipoproteins and triglyceride values were significantly increased when compared with those without pituitary failure after treatment (p<0.001). In our study, it was found that there was increased metabolic and cardiovascular risk in functional pituitary adenoma and NFA.
  • ||||||||||  Journal:  Low-Dose Gamma Knife Radiosurgery for Acromegaly. (Pubmed Central) -  Mar 26, 2020   
    Reasonable remission and new hormone deficiency rates can be achieved with low-dose GKRS for acromegaly. These rates may be comparable to those with standard GKRS margin doses.
  • ||||||||||  Clinical, Journal:  Acromegaly caused by a somatotroph adenoma in patient with neurofibromatosis type 1. (Pubmed Central) -  Mar 24, 2020   
    Although any mutations of the following genes; MEN1, CDKN1B, and PAX8-PPARγ were not detected, a heterozygous GNAS R201C mutation was detected in the somatotroph adenoma. To our knowledge, this is the first rare MEN1-like case of genetically diagnosed NF1 complicated with acromegaly caused by a somatotroph adenoma.
  • ||||||||||  Journal:  Acromegaly in Carney complex. (Pubmed Central) -  Mar 24, 2020   
    To our knowledge, this is the first rare MEN1-like case of genetically diagnosed NF1 complicated with acromegaly caused by a somatotroph adenoma. Although it rarely reveals CNC, acromegaly is diagnosed at a younger age in this setting, with a higher proportion of microadenomas.
  • ||||||||||  Somavert (pegvisomant) / Pfizer
    Review, Journal:  MANAGEMENT OF ENDOCRINE DISEASE: Does gender matter in the management of acromegaly. (Pubmed Central) -  Mar 24, 2020   
    Mortality in untreated acromegaly is more profoundly affected in women, however improved treatments in recent decades has resulted in normalisation of standard mortality ratios in both sexes. We conclude that gender does matter in the management of acromegaly, with women presenting later in life, with greater diagnostic delay, higher prevalence of comorbidities and experiencing worse QoL.
  • ||||||||||  Journal:  Radiosurgery as primary management for Acromegaly. (Pubmed Central) -  Mar 20, 2020   
    STRS has shown good long-term efficacy providing initial control can be afforded by optimal medical management. While TSS remains best practice, STRS offers an alternative for those in whom surgery is not an option.
  • ||||||||||  Journal:  Endocrinology of Hirsutism: From Androgens to Androgen Excess Disorders. (Pubmed Central) -  Mar 19, 2020   
    This paper provides an overview of the principal endocrinological aspects of hirsutism including the role of androgens in excessive hair growth and associated androgen excess disorders. Clinical evaluation and management of hirsutism are also discussed.
  • ||||||||||  Clinical, Journal:  Androgens in Menopausal Women: Not Only Polycystic Ovary Syndrome. (Pubmed Central) -  Mar 19, 2020   
    Imaging techniques are used to localize the source of androgens: computed tomography and magnetic resonance imaging (MRI) for the adrenals and transvaginal ultrasound or MRI for the ovaries. Finally, treatment (etiologic and symptomatic) and long-term effects of hyperandrogenism are developed in this chapter.
  • ||||||||||  Legalon (silibinin) / Mylan
    Review, Journal:  Geoffrey Harris Award 2019: Translational research in pituitary tumors. (Pubmed Central) -  Mar 17, 2020   
    Regarding the well-known resistance of a part of somatotropinomas to somatostatin analogue treatment, recently identified mechanisms responsible for the drug resistance are summarized and ways to overcome them in future treatment concepts are presented. Concerning novel therapeutic options for patients with Cushing's disease the impact of retinoic acid, which is currently tested in clinical studies, is shown, and the action and putative therapeutic impact of silibinin to resolve glucocorticoid resistance in these patients is critically discussed.
  • ||||||||||  Somavert (pegvisomant) / Pfizer, NN1213 / Novo Nordisk
    Trial completion date, Trial primary completion date:  I-Con Study: Strict IGF-1 Control in Acromegaly (clinicaltrials.gov) -  Mar 17, 2020   
    P3,  N=35, Recruiting, 
    Our cohort data suggest that regular MRI follow-up does not seem relevant in patients with acromegaly who are responsive to SMSa treatment. Trial completion date: Jan 2020 --> Jan 2021 | Trial primary completion date: Dec 2019 --> Dec 2020
  • ||||||||||  Trial completion:  Olfactory Function and Olfactory Bulb Volume in Acromegaly Patients (clinicaltrials.gov) -  Mar 16, 2020   
    P=N/A,  N=40, Completed, 
    Trial completion date: Jan 2020 --> Jan 2021 | Trial primary completion date: Dec 2019 --> Dec 2020 Recruiting --> Completed
  • ||||||||||  Review, Journal:  Therapeutic Targeting of the IGF Axis. (Pubmed Central) -  Mar 12, 2020   
    We outline the advantages and disadvantages of each approach, and discuss progress in evaluating these agents, including factors that contributed to the failure of many of these novel therapeutics in early phase cancer trials. Finally, we summarize grounds for cautious optimism for ongoing and future studies of IGF blockade in cancer and non-malignant disorders including thyroid eye disease and aging.
  • ||||||||||  Somavert (pegvisomant) / Pfizer, Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin, Signifor LAR (pasireotide) / Novartis
    [VIRTUAL] MEDICATIONS FOR ACROMEGALY- COST-UTILITY AND VALUE OF INFORMATION ANALYSIS () -  Mar 8, 2020 - Abstract #ISPOR2020ISPOR_1148;    
    No second-line treatment is recommended. Significant uncertainty of parameters impairs optimal decision-making, and this conclusion can be generalized to other countries.
  • ||||||||||  Signifor LAR (pasireotide) / Novartis
    Review, Journal:  Cardiometabolic Risk in Acromegaly: A Review With a Focus on Pasireotide. (Pubmed Central) -  Mar 3, 2020   
    In this regard, pasireotide was shown to significantly influence glucose metabolism. This review summarizes the cardiometabolic consequences of acromegaly and its treatment, focusing on available data around the effects of medical therapy with pasireotide on factors that influence cardiometabolic risk.
  • ||||||||||  bromocriptine / Generic mfg.
    Clinical, Retrospective data, Journal:  Clinical characteristics of acromegalic patients with paradoxical growth hormone response to oral glucose load. (Pubmed Central) -  Mar 2, 2020   
    GH levels during octreotide or bromocriptine testing were decreased more significantly in OG responders than in nonresponders (P < 0.05, P < 0.05, respectively)...Paradoxical GH response reflected the clinical characteristics, especially IGF-I levels, glucose metabolism and drug efficacy in acromegaly. Paradoxical GH response, in addition to the nadir GH levels, to OG load can be potentially useful for evaluation of the clinical characteristics of acromegaly.